title: [Treatment of chronic myeloid leukemia in chronic phase].
authors.forename: Itaru
authors.initials: I
authors.lastname: Matsumura
mesh_terms: D064591:Allografts; D001549:Benzamides / Q000008:administration & dosage*; D002066:Busulfan / Q000008:administration & dosage; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D000069439:Dasatinib; D015195:Drug Design; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D058990:Molecular Targeted Therapy; D010879:Piperazines / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D013844:Thiazoles / Q000008:administration & dosage; D014178:Translocation, Genetic
chemical_list: D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D002066:Busulfan; D000069439:Dasatinib; D006918:Hydroxyurea